

Anterior Uveitis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight

DelveInsight's Anterior Uveitis Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LA, UNITED STATES, June 21, 2024 /EINPresswire.com/ --

DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



Anterior Uveitis Market

To Know in detail about the Anterior Uveitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Anterior Uveitis Market Forecast](#)

Some of the key facts of the Anterior Uveitis Market Report:

The Anterior Uveitis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

DelveInsight's analysis indicates that in 2022, there were 1,013,902 total diagnosed prevalent cases of uveitis in the 7MM, with anticipated growth by 2034.

In 2022, within the 7MM, the United States reported around 382,883 total diagnosed prevalent cases of uveitis, with projections for changes in these numbers during the forecast period.

Among the EU4 countries and the UK, France recorded the highest diagnosed prevalent cases of uveitis in 2022, with around 88,797 cases, anticipated to rise by 2034. Spain reported the lowest number of cases, approximately 75,461 during the study period.

According to DelveInsight's analysis, the United States recorded the highest number of anterior uveitis cases in 2022, totaling 258,829. These figures are projected to fluctuate during the forecast period from 2023 to 2034.

In 2022, the EU4 countries and the UK collectively reported around 203,551 diagnosed prevalent

cases of anterior uveitis. Projections indicate that these numbers will undergo changes during the forecast period from 2023 to 2034.

According to DelveInsight's analysis, within the 7MM, idiopathic etiology constituted the highest number of uveitis cases, totaling about 430,676 in 2022, while JIA represented the fewest cases, approximately 17,641. These figures are projected to rise by 2034.

Key Anterior Uveitis Companies: Tarsier Pharma, Oculis Pharma, Eli Lilly and Company, ESBA Tech AG, Alcon Research, Eyegate Pharmaceuticals, Lux Biosciences, Inc., Massachusetts Eye Research, Aldeyra Therapeutics, Inc., Priovant Therapeutics, Inc., ACELYRIN Inc., Eli Lilly and Company, UCB Biopharma SRL, Novartis, and others

Key Anterior Uveitis Therapies: TRS01, Licaminlimab (OCS-02), OLUMIANT (baricitinib), ESBA105, LME636, EGP-437, LX211, Ixekizumab Prefilled Syringe, NS2, Brepocitinib, Izokibep, Baricitinib, Certolizumab Pegol, AIN457, and others

The Anterior Uveitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Anterior Uveitis pipeline products will significantly revolutionize the Anterior Uveitis market dynamics.

Anterior Uveitis Overview

Anterior uveitis, also known as iritis, is an inflammation of the uvea, specifically affecting the front portion of the eye. The uvea is the middle layer of the eye that includes the iris (colored part of the eye), ciliary body, and choroid. Anterior uveitis primarily involves inflammation of the iris and adjacent tissue.

Get a Free sample for the Anterior Uveitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Anterior Uveitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Anterior Uveitis Epidemiology Segmentation:

The Anterior Uveitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Anterior Uveitis

Prevalent Cases of Anterior Uveitis by severity

Gender-specific Prevalence of Anterior Uveitis

Diagnosed Cases of Episodic and Chronic Anterior Uveitis

Download the report to understand which factors are driving Anterior Uveitis epidemiology trends @ [Anterior Uveitis Epidemiology Forecast](#)

Anterior Uveitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anterior Uveitis market or expected to get launched during the study period. The analysis covers Anterior Uveitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Anterior Uveitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Anterior Uveitis Therapies and Key Companies

TRS01: Tarsier Pharma

Licaminlimab (OCS-02): Oculis Pharma

OLUMIANT (baricitinib): Eli Lilly and Company

ESBA105: ESBATech AG

LME636: Alcon Research

EGP-437: Eyegate Pharmaceuticals

LX211: Lux Biosciences, Inc.

Ixekizumab Prefilled Syringe: Massachusetts Eye Research

NS2: Aldeyra Therapeutics, Inc.

Izokibep: ACELYRIN Inc.

Baricitinib: Eli Lilly and Company

Certolizumab Pegol: UCB Biopharma SRL

Brepocitinib: Priovant Therapeutics, Inc.

AIN457: Novartis

Anterior Uveitis Market Strengths

The remarkable advances in ocular immunology over the past decades have led to a better understanding of the molecular mechanisms that underlie etiology and susceptibility to anterior uveitis.

Advances in disease nomenclature for classification, clinical trials, drug delivery systems, multimodality diagnostic imaging, and laboratory testing involving “omics” technology have provided insight into disease pathogenesis.

Anterior Uveitis Market Opportunities

Opportunity for companies to implement knowledge from recent advances in understanding the etiologies associated with anterior uveitis to evaluate potential drugs with novel targets.

The increasing prevalence, along with initiatives to increase awareness of the disease, provide an opportunity to improve the pathogenesis of the disease.

Scope of the Anterior Uveitis Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Anterior Uveitis Companies: Tarsier Pharma, Oculis Pharma, Eli Lilly and Company, ESBA Tech AG, Alcon Research, Eyegate Pharmaceuticals, Lux Biosciences, Inc., Massachusetts Eye Research, Aldeyra Therapeutics, Inc., Priovant Therapeutics, Inc., ACELYRIN Inc., Eli Lilly and Company, UCB Biopharma SRL, Novartis, and others

Key Anterior Uveitis Therapies: TRS01, Licaminlimab (OCS-02), OLUMIANT (baricitinib), ESBA105, LME636, EGP-437, LX211, Ixekizumab Prefilled Syringe, NS2, Brepocitinib, Izokibep, Baricitinib, Certolizumab Pegol, AIN457, and others

Anterior Uveitis Therapeutic Assessment: Anterior Uveitis current marketed and Anterior Uveitis emerging therapies

Anterior Uveitis Market Dynamics: Anterior Uveitis market drivers and Anterior Uveitis market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Anterior Uveitis Unmet Needs, KOL's views, Analyst's views, Anterior Uveitis Market Access and Reimbursement

To know more about Anterior Uveitis companies working in the treatment market, visit @ [Anterior Uveitis Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Anterior Uveitis Market Report Introduction
2. Executive Summary for Anterior Uveitis
3. SWOT analysis of Anterior Uveitis
4. Anterior Uveitis Patient Share (%) Overview at a Glance
5. Anterior Uveitis Market Overview at a Glance
6. Anterior Uveitis Disease Background and Overview
7. Anterior Uveitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Anterior Uveitis
9. Anterior Uveitis Current Treatment and Medical Practices
10. Anterior Uveitis Unmet Needs
11. Anterior Uveitis Emerging Therapies
12. Anterior Uveitis Market Outlook
13. Country-Wise Anterior Uveitis Market Analysis (2020–2034)
14. Anterior Uveitis Market Access and Reimbursement of Therapies
15. Anterior Uveitis Market Drivers
16. Anterior Uveitis Market Barriers
17. Anterior Uveitis Appendix
18. Anterior Uveitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/721919225>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.